CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-01 | LEONARD JOHN M President and CEO | Grant or award | +40,990 | 765,650 | ||
| 2022-03-01 | LEONARD JOHN M President and CEO | Grant or award · Stock Option (right to buy) | +59,941 | 59,941 | ||
| 2022-03-01 | Goddard Glenn EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +18,600 | 18,600 | ||
| 2022-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +20,203 | 20,203 | ||
| 2022-03-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +20,203 | 20,203 | ||
| 2022-03-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award | +13,816 | 18,631 | ||
| 2022-03-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +13,816 | 13,816 | ||
| 2022-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +13,816 | 24,738 | ||
| 2022-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +13,816 | 13,816 | ||
| 2022-03-01 | Goddard Glenn EVP, Chief Financial Officer | Grant or award | +12,720 | 14,769 | ||
| 2022-03-01 | Goddard Glenn EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +12,720 | 12,720 | ||
| 2022-03-01 | BASTA JAMES EVP, General Counsel | Grant or award | +11,049 | 11,049 | ||
| 2022-03-01 | BASTA JAMES EVP, General Counsel | Grant or award | +9,648 | 20,697 | ||
| 2022-03-01 | BASTA JAMES EVP, General Counsel | Grant or award · Stock Option (right to buy) | +9,648 | 9,648 | ||
| 2022-01-03 | Hicks Derek EVP, Chief Business Officer | Grant or award | +19,118 | 19,118 | ||
| 2022-01-03 | Hicks Derek EVP, Chief Business Officer | Grant or award · Stock option (right to buy) | +25,000 | 25,000 | ||
| 2022-01-01 | LEONARD JOHN M President and CEO | Option exercise | +7,848 | 727,153 | ||
| 2022-01-01 | LEONARD JOHN M President and CEO | Sale | −2,493 | $112.26 | $280K | 724,660 |
| 2022-01-01 | LEONARD JOHN M President and CEO | Option exercise · Restricted Stock Unit | −7,848 | 23,546 | ||
| 2022-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise | +3,500 | 5,963 |
Page 13 of 40 · 783 trades